Comparative Pharmacology
Head-to-head clinical analysis: IGALMI versus LOFEXIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IGALMI versus LOFEXIDINE HYDROCHLORIDE.
IGALMI vs LOFEXIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the central nervous system, resulting in decreased agitation and sedation.
Alpha-2 adrenergic receptor agonist; reduces central sympathetic outflow by binding to presynaptic alpha-2 receptors in the brainstem, decreasing norepinephrine release.
Sublingual: 120 mcg to 180 mcg as a single dose, administered under the tongue, one time. Maximum single dose: 180 mcg.
0.2 mg orally twice daily, titrate by 0.2-0.4 mg/day every 1-2 days to maximum 2.4 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is 2.5 to 3.5 hours in healthy subjects, with prolonged half-life in patients with hepatic impairment (up to 5-7 hours) or renal impairment (up to 6-8 hours).
Terminal elimination half-life is 11-13 hours in patients with normal renal function; prolonged to up to 40 hours in renal impairment.
Approximately 75% of the dose is excreted renally as unchanged drug, with the remainder eliminated via biliary/fecal routes (approximately 20%) and minor metabolic clearance.
Primarily renal (approximately 80-90% as unchanged drug and metabolites, with 20-30% unchanged); minor fecal excretion (<5%).
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist